46 results on '"Baas P"'
Search Results
2. First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?
3. Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum–gemcitabine chemotherapy
4. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute
5. Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study
6. I love my dog
7. Targeting BAP1: a new paradigm for mesothelioma
8. 152 Clinical prediction for acute toxicity in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiation
9. 5IN ESMO NON-SMALL-CELL LUNG CANCER (NSCLC) CONSENSUS ON PATHOLOGY AND MOLECULAR TESTING
10. 3IN ADVANCED NSCLC
11. 27 Potential pitfalls in the evaluation of new drugs for mesothelioma: Lessons from the past
12. 139 Occupational asbestos exposure, possible mesothelioma and reimbursement
13. 195 The current status of mesothelioma clinical trials in Europe
14. 131 Malignant mesothelioma as a second primary malignancy
15. 10 ALA mediated fluorescence thoracoscopy in pleural diseases
16. P-392 Pemetrexed with or without a platinum compound in patients with malignant mesothelioma: A single institution “Expanded Access Program” experience
17. PD-151 Mutations in the epidermal growth factor receptor (EGFR): Retro-and prospective observations in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib
18. P-836 Permanent Pleurx catheters for recurrent malignant pleural effusion
19. P-348 Fluorescence detection of pleural disease using 5-ALA
20. 33 Survival of patients with malignant pleural mesothelioma (MPM)after extensive surgical resection with radiotherapy (EPP+RT)
21. 31 Occupational malignant mesothelioma cases; Review by Dutchpulmonologists of undefined cases in the framework of a reimbursement program of the Netherlands Institute of Asbestos Victims
22. O-293 Follow-up of a phase I/II dose escalation trial in non-small cell lung cancer using 3D conformal radiotherapy
23. Report from the First Meeting of the ‘European Network on Translational Research in Lung Cancer Amsterdam–Barcelona–Bialystok–Heidelberg’
24. Randomized phase I study of weekly or every other week gemcitabine (GEM) plus cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC)
25. Second-line treatment with single-agent gemcitabine (GEM) in patients (PTS) with advanced non-small-cell lung cancer (NSCLC)
26. Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM)
27. Malignant Pleural Mesothelioma (MPM) treatment with Extrapleural pneumonectomy (EPP) and intra-operative Photodynamic therapy (iPDT) using mTHPC as photosensitiser: Long term outcome and toxicity
28. Dose escalation in NSCLC using three dimensional conformal radiotherapy (3 DCRT)
29. 326 Photodynamic therapy (PDT) as adjuvant treatment for resected malignant mesothelioma: A dose finding study with m-THPC
30. Predicting pulmonary toxicity of radiation
31. 641 Tumor markers in malignant mesothelioma — Their usefulness
32. 48 Phase II trials of etoposide in malignant pleural mesothelioma
33. 57 Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study
34. 729 Aromatic DNA adduct levels in alveolar macrophages and lymphocytes of smoking volunteers; Effects of N-acetylcysteine (NAC) supplementation
35. Distribution of 99mTc Colloid in the thoracic cavity of patients with malignant pleural effusions
36. Tumour markers in mesothelioma
37. Actinomycosis, a sheep in wolves' clothes
38. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer
39. The prognostic significance of a previous malignancy in operable non-small cell lung cancer
40. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma
41. Distribution of ^9^9^mTc Colloid in the thoracic cavity of patients with malignant pleural effusions
42. Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM)
43. Randomized phase I study of weekly or every other week gemcitabine (GEM) plus cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC)
44. Second-line treatment with single-agent gemcitabine (GEM) in patients (PTS) with advanced non-small-cell lung cancer (NSCLC)
45. Tracheal obstruction after placement of a metal wire expandable stent (Wallstent)
46. Endobronchial treatment of lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.